| Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. | |
| | |
MedLine Citation:
|
PMID: 10545429 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND:Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS:In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardial infarction), INJECT (INternational Joint Efficacy Comparison of Thrombolytics), and GUSTO-3 (Global Use of Strategies To Open occluded coronary arteries) trials, 126 patients were enrolled in a single center. Patients were treated with either conventional alteplase (100 mg/180 min; n=15), accelerated alteplase (100 mg/90 min; n=21), reteplase 10+10-U double bolus (n=50), reteplase 10+5-U double bolus (n=15), reteplase 15-U single bolus (n=15), or streptokinase (1.5 MU/60 min; n=10). PA (after stimulation with ADP), P-selectin expression and fibrinogen binding to glycoprotein (GP) IIb/IIIa (determined by flow cytometry with and without stimulation with ADP), and levels of soluble P-selectin, prothrombin fragments F1 and F2, thrombin-antithrombin complexes (TAT), and antithrombin III (ATIII) were determined. PA decreased significantly at 1 and 2 hours in patients treated by 10+10-U reteplase or by streptokinase. Fibrinogen binding to platelet GP IIb/IIIa followed a similar pattern. Significant thrombin generation and significantly elevated thrombin levels during thrombolysis were reflected by increased F1 and F2 fragments and TAT levels in all treatment groups. ATIII levels decreased significantly during thrombolytic therapy. CONCLUSIONS:A decrease in PA in patients treated by reteplase or streptokinase compared with alteplase could be observed in the early phase. Double bolus (10+10 U) reteplase and streptokinase resulted in lower PA at 1 and 2 hours than therapy with accelerated alteplase. Total fibrinogen and fibrinogen binding to GP IIb/IIIa tended to be lower during the first 2 hours after reteplase than after accelerated alteplase. |
| | |
Authors:
|
M Moser; T Nordt; K Peter; J Ruef; B Kohler; M Schmittner; R Smalling; W Kübler; C Bode |
Related Documents
:
|
8759069 - Beneficial effects of rheothrx injection in patients receiving thrombolytic therapy for... 1739049 - Thrombolytic therapy in acute myocardial infarction. 7480969 - Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents. 1729879 - Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients ... 7904119 - Early intravenous beta blockade and thrombolytics in acute myocardial infarction. 17640539 - Thrombolysis in acute myocardial infarction: current status. 22423609 - Innate immunity markers in culprit plaques of acute myocardial infarction or stable ang... 9630099 - Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 japane... 8398509 - Complications of diagnostic cardiac catheterisation: results from 34,041 patients in th... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Circulation Volume: 100 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-11-18 Completed Date: 1999-11-18 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1858-64 Citation Subset: AIM; IM |
Affiliation:
|
Internal Medicine III (Cardiology), University of Heidelberg, Heidelberg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Double-Blind Method Fibrinogen / metabolism* Humans Middle Aged Myocardial Infarction / blood, drug therapy* P-Selectin / metabolism Platelet Activation / drug effects* Platelet Aggregation / drug effects* Platelet Glycoprotein GPIIb-IIIa Complex / metabolism* Protein Binding Recombinant Proteins / therapeutic use Streptokinase / therapeutic use Thrombolytic Therapy* Tissue Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/P-Selectin; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 133652-38-7/reteplase; 9001-32-5/Fibrinogen; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vascular effects of estrogen and vitamin E therapies in postmenopausal women.
Next Document: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass...